WO1991019982A1 - Procede de determination de polypeptides et de proteines dans les solutions et les fluides biologiques - Google Patents

Procede de determination de polypeptides et de proteines dans les solutions et les fluides biologiques Download PDF

Info

Publication number
WO1991019982A1
WO1991019982A1 PCT/EP1991/001100 EP9101100W WO9119982A1 WO 1991019982 A1 WO1991019982 A1 WO 1991019982A1 EP 9101100 W EP9101100 W EP 9101100W WO 9119982 A1 WO9119982 A1 WO 9119982A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
analyte
polypeptide
protein
peptide
Prior art date
Application number
PCT/EP1991/001100
Other languages
English (en)
Inventor
Francesco Della Valle
Lanfranco Callegaro
Original Assignee
Fidia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia S.P.A. filed Critical Fidia S.P.A.
Publication of WO1991019982A1 publication Critical patent/WO1991019982A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Definitions

  • the present invention relates to analytical methods for qualitatively and quantitatively determining the presence of polypeptides and proteins in solutions and biological fluids.
  • it relates to a competitive-type analytical assay system employing antibodies specific for a portion of the amino acid sequence of a polypeptide or protein, and the polypeptide, protein, or a portion thereof as an analytical reagent.
  • the presence or concentration of antigenic substances in biological fluids can be determined by immunoassay techniques. Such techniques are based on the formation of a complex between the antigenic substance being assayed and an antibody in which a member of the complex may be labelled to permit detection or quantitative analysis after separation of the complexed labelled antigen or antibody from uncomplexed labelled antigen or antibody.
  • the antigenic substance in a sample test fluid competes with a known quantity of labelled antigen for a limited quantity of antibody binding sites. Consequently, the amount of labelled antigen bound to the antibody is inversely proportional to the amount of antigen in the sample.
  • immunometric assays employ a labelled antibody, and the amount of labelled antibody associated with the complex is directly proportional to the amount of antigenic substance in the sample fluid.
  • hydrophilic regions are normally exposed on the surface of the protein molecule, they are likely to exercise a particular biological function. It may be expected, for example, that they could act as receptor binding regions, or that they represent antigenic sites, capable of inducing the formation of specific antibodies.
  • Hopp and Woods ((1961) Proc, Natl. Acad. Sci. USA 78:3824) developed an algorithm which is capable of producing the hydrophilic profile of a protein molecule, thus making it possible to assess whether a given peptide of the polypeptide chain tends to place itself on the surface or in the interior of the protein structure.
  • This method takes into consideration a peptide chain between 6 and 10 amino acid residues long, calculating its hydrophilic value by the coefficients assigned to the single amino acid residues. By shifting section by section along the sequence one amino acid at a time, a complete diagram can be obtained (Meier R.
  • NGF nerve growth factor
  • the "competitive" system is certainly the most sensitive in terms of specificity. Determination of an analyte in biological liquids by a competitive-type reaction system is performed by incubating the sample, with or without analyte, with a support to which anti-analyte antibodies are bound, usually defined as the solid phase. Subsequently, when the analyte which has not reacted with the antibodies has been eliminated, the solid phase is washed with suitable buffers and incubated with the analyte in question, which can be directly or indirectly labelled with a visualizing agent, for example with a biotin-avidin-enzyme system (Johnson B. et al., J. Immunol.
  • step (c) removing any unreacted biological fluid or solution and labelled peptide fragments from the reaction mixture of step (b);
  • step (e) qualitatively and quantitatively detecting or measuring said antibody complexes of step (d).
  • a disease such as a neuroimmunoendocrine disease, a neuroimmunodegenerative disease, a disease of the central nervous system, or a disease of the peripheral nervous system in a human or animal
  • kit for the qualitative or quantitative determination of a polypeptide or protein analyte present in a biological fluid or solution comprising:
  • anti-analyte antibodies specific for a peptide fragment of said polypeptide or protein analyte which are capable of recognizing said polypeptide or protein analyte; and a peptide fragment which is capable of being recognized by said antibodies, and which is also capable of being detected by a detection system.
  • Figure 1 shows the reactivity of human NGF antipeptide 20-36 polyclonal antibodies compared to that of polyclonal antibodies produced by immunization with the 2.5S form of NGF against human NGF in a Western blot: a) polyclonal antibodies produced in rabbit by immunization with NGF peptide 20-36; b) polyclonal antibodies produced in rabbit by immunization with the 2.5S form of NGF and purified by affinity chromatography on peptide 20-36 immobilized on a solid support and on immobilized NGF, respectively. The presence of polyclonal antibodies was detected by means of a commercially available amplification system.
  • Detection system blotted proteins were visualized with anti-rabbit AuroProbe BL plus secondary antibodies (Janssen) following the manufacturer's instructions.
  • Figure 2 is a standard curve showing absorbance readings at 492 nm for samples treated as described in
  • Example 1 infra, disclosing a linear correspondence between the analyte, human NGF, and optical density in the presence competitive immunological assay system.
  • Bo absorbance value (in nm) of the standard concentration of the tracer (peptide 20-36 labelled with biotin);
  • the purpose of the present invention is to provide an assay for a soluble polypeptide or protein or their fragments based on the calculation of the hydropathic profile derived from its gene sequence and the consequent amino acid sequence.
  • the invention is illustrated hereafter by Examples 1 and 2, and exemplifies the assay of the biologically active form of human NGF obtained by recombinant DNA methodology (Italian patent application No. 48564A89). Moreover, within the context of the present invention, the use of NGF must be considered illustrative and not limiting in any way, since the experimental approach on which the invention is based can be applied to all polypeptides and proteins.
  • NGF from mouse glands behaves as a 7S-type protein complex (molecular weight about 140,000 Daltons) formed by three different subunits ( ⁇ , ⁇ , ⁇ ) coordinating a Zn + atom.
  • the most interesting part of the 7S molecule consists of two polypeptide chains, each with a molecular weight of 13,250 Daltons and formed by 118 amino acids. Each chain or monomer has three disulfide bridges, which form covalent bonds between two cysteine residues, and which confer great stability to the three-dimensional structure of the protein.
  • the amino acid portion identifiable as 20-36 i.e., the amino acids at positions 20-36 of the NGF polypeptide, was chosen to illustrate the utility of the present invention.
  • the synthetic peptide 20-36 of NGF can be used to produce polyclonal antibodies capable of selectively recognizing and interacting not only with the peptide itself, but also with the entire NGF molecule. This fragment is common to a variety of animal species, facilitating analysis of the NGF protein therein.
  • anti-NGF antibodies used in the solid phase, infra i.e., adsorbed onto the support, were produced by immunizing rabbits via multiple site intradermal injections of the free peptide, absent a carrier, in complete Freund's adjuvant, with a specific NGF fragment, a peptide comprising the amino acid sequence corresponding to portion
  • NGF in its biologically active form, 2.5S or ßNGF, cloned and expressed in eukaryotic cells (Italian patent application No. 48564A89).
  • Assessment of the reactivity of these NGF anti-peptide 20-36 polyclonal antibodies is shown in Figure 1, where it can be seen that rabbit polyclonal antibodies produced by immunization with either NGF peptide 20-36 or the 2.5S form of NGF exhibit the same reactivity with human NGF upon Western blotting.
  • the concentration of antibody used to adsorb to the wells ranged between 0.1-10 ⁇ g/ml, preferably 1 ⁇ g/ml, in carbonate buffer, 0.1M, pH 8.5.
  • Wells were coated with 20 ⁇ l-100 ⁇ l, preferably 50 ⁇ l, of this solution.
  • the value of 50 ⁇ l corresponds to 50 ng/well, indicated in Fig. 2.
  • analyte sample 50 ⁇ l of analyte sample, at different concentrations, were placed in the wells of the microtitration plate in the presence of peptide 20-36 labelled with biotin (hapten-peptide), and left to incubate for 24 hours at room temperature.
  • the concentration of NGF ranged between 0.1-100 ng/ml.
  • the buffer employed was PBS, containing 0.1% bovine serum albumin.
  • the quantity of labelled peptide 20-36 ranged from 2-20 ng/ml, preferably 10 ng/ml. This corresponded to 0.5 ng/well.
  • the wells prepared as described in Section A.2. were filled with 50 ⁇ l of a commercially obtained tracer composed of avidin-labelled enzyme, such as horseradish peroxidase diluted in 0.15M phosphate buffer, pH 7.2, containing 0.05 % Tween 20 and 2% bovine albumin. This was incubated for 4 to 6 hours at room temperature or at 37oc. Any excess reagent was removed by washing with 0.15M phosphate buffer, pH 7.2.
  • avidin-labelled enzyme such as horseradish peroxidase diluted in 0.15M phosphate buffer, pH 7.2, containing 0.05 % Tween 20 and 2% bovine albumin.
  • the wells treated as described in Section A.3. were filled with 50 ⁇ l of a mixture of 0.4 mg/ml of orth ⁇ phenylenediamine and 0.2 mg/ml of hydrogen peroxide in 0.1M citrate buffer at pH 5.0. After incubation for 15 minutes, 50 ⁇ l of sulfuric acid, 2.5 mol./litri, were added to the wells of the microtitration plates. A.5. Absorbance measurement.
  • the present invention also concerns a kit containing components necessary to detect the protein or polypeptide of interest.
  • This kit must at least contain anti-peptide antibodies unbound or bound to a support, and the analyte polypeptide or protein, or one of their specific segments, bound to a labelling agent.
  • Human NGF was determined as described in Example 1 using a multi-assay kit. This kit contained the following:
  • NGF in its form known as 2.5S or BNGF, and its non-dimeric forms
  • a support for example, tubes, microtitration plates or their strips, beads or disks made of glass, plastic, or other substances suitable for this purpose.
  • the antibody does not necessarily have to be bound to a support, and can be present free in solution. Should the antibodies not be bound to a support, it is necessary to utilize a chemical or biological precipitating agent such ae polyethylene glycol, or a complexing agent such as protein-A or protein-G.
  • labelling/detection agents it is possible to use enzymes such as horseradish peroxidase, ⁇ -galactosidase, or alkaline phosphatase, fluorescent substrates, fluorogenic, chemiluminescent, bioluminescent, radioactive, or metallic molecules, or biotin.
  • a kit can contain aids for the determination of labelling agents, for example a substrate for the enzyme, and washing or dilution buffers which may or may not contain detergents.
  • Any polypeptide or protein analyte can be qualitatively and/or quantitatively detected by the method of the present invention.
  • proteins which can be detected by the method of the present invention include, but are not limited to, for example, soluble cytokines and growth factors, including the nerve growth factor of human origin.
  • soluble cytokines and growth factors including the nerve growth factor of human origin.
  • antibodies can be raised against such selected peptide fragments.
  • the extent of cross-reactivity of these antibodies with the entire polypeptide or protein molecule can be determined by routine immunological methods.
  • peptide sequences that result in the production of antibodies that effectively cross-react with the entire analyte molecule are useful in the present method and kit, and can be employed in the qualitative and/or quantitative detection of polypeptide or protein analytes as described herein.
  • the qualitative and quantitative detection of proteins of medical and veterinary significance via the instant method provides a valuable rapid diagnostic tool permitting the diagnosis and monitoring of a wide variety of diseases and therapies.
  • the latter include, but are not limited to, diseases of the neuroimmunoendocrine type, the neuroimmunodegenerative type, such as Alzheimer's disease, multiple sclerosis, Huntington's disease, motoneuron disease, Guillain Barre syndrome, and Parkinson's disease, diseases of the central nervous system, such as those of traumatic, anoxic, degenerative, or toxic-infective origin, diseases of the peripheral nervous system, such as those of traumatic-compressive, degenerative, dysmetabolic, or toxic-infective origin, etc.
  • a further advantage of the present inventive method derives from the fact that the peptide sequence employed to produce the antibodies necessary to carry out the analysis of an analyte-containing fluid can be generated from the nucleotide sequence of the target protein or polypeptide. Knowledge of the amino acid sequence of the protein or polypeptide, or availability of the analyte itself, which may be very expensive or in limited supply, is not required. Furthermore, such antibodies can be obtained by immunization with a peptide without the use of adjuvants. Finally, the length of the peptide fragment required is short, varying between 8-30, and preferably about 17, amino acids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé de détermination qualitative et quantitative d'une substance polypeptidique ou protéique soumise à l'analyse et présente dans une solution ou un fluide biologique. On utilise un système d'analyse du type à compétition dans lequel le réactif compétitif est un fragment peptidique marqué et présent dans le séquence d'aminoacides de ladite substance. Par exemple, le procédé consiste à déterminer le facteur de croissance nerveuse chez l'homme. On a prévu un kit destiné à la détermination des substances polypeptidiques ou protéiques soumises à l'analyse, à l'aide de ce procédé, ainsi qu'un procédé utile dans le domaine de la médecine humaine et vétérinaire lors du diagnostic et/ou de la surveillance de diverses maladies et de traitements correspondants dans lesquels un polypeptide ou une protéine caractéristique peut servir de moyen de diagnostic efficace.
PCT/EP1991/001100 1990-06-12 1991-06-12 Procede de determination de polypeptides et de proteines dans les solutions et les fluides biologiques WO1991019982A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT04162690A IT1243281B (it) 1990-06-12 1990-06-12 Metodo per la determinazione quantitativa e qualitativa di polipeptidiin liquidi proteici
IT41626A/90 1990-06-12

Publications (1)

Publication Number Publication Date
WO1991019982A1 true WO1991019982A1 (fr) 1991-12-26

Family

ID=11252188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001100 WO1991019982A1 (fr) 1990-06-12 1991-06-12 Procede de determination de polypeptides et de proteines dans les solutions et les fluides biologiques

Country Status (6)

Country Link
EP (1) EP0533779A1 (fr)
CN (1) CN1058846A (fr)
AU (1) AU7969091A (fr)
IL (1) IL98466A0 (fr)
IT (1) IT1243281B (fr)
WO (1) WO1991019982A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1050757A1 (fr) * 1999-05-03 2000-11-08 Evotec BioSystems AG Méthodes de diagnostic ou de traitement de maladies neuropsychiatriques basées sur des taux accrus du NGF (Nerve Growth Factor) dans la fluide cérébrospinale
WO2000067033A1 (fr) * 1999-05-03 2000-11-09 Evotec Biosystems Ag Procedes permettant de diagnostiquer ou traiter la maladie d'alzheimer
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003430A1 (fr) * 1987-10-13 1989-04-20 Terrapin Diagnostics, Ltd. Procede de production de reactifs pour diagnostics d'immunite
EP0345906A2 (fr) * 1988-06-10 1989-12-13 Merck & Co. Inc. Antigènes spécifiques du site de coupure unique du fibrinogène par l'élastase
WO1990010644A1 (fr) * 1989-03-14 1990-09-20 Lope Medicine Ab Peptides et anticorps de detection de fcn (facteur de croissance de nerfs) et/ou de precurseurs de celui-ci
EP0418590A1 (fr) * 1989-08-28 1991-03-27 Takeda Chemical Industries, Ltd. Anticorps, leur production et utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003430A1 (fr) * 1987-10-13 1989-04-20 Terrapin Diagnostics, Ltd. Procede de production de reactifs pour diagnostics d'immunite
EP0345906A2 (fr) * 1988-06-10 1989-12-13 Merck & Co. Inc. Antigènes spécifiques du site de coupure unique du fibrinogène par l'élastase
WO1990010644A1 (fr) * 1989-03-14 1990-09-20 Lope Medicine Ab Peptides et anticorps de detection de fcn (facteur de croissance de nerfs) et/ou de precurseurs de celui-ci
EP0418590A1 (fr) * 1989-08-28 1991-03-27 Takeda Chemical Industries, Ltd. Anticorps, leur production et utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D.T. Krieger et al.: "Brain Peptides", 1983, chapter 20, O.P. Rorstad: "Competitive binding assays", pages 465-483, see pages 466-473 *
Journal of Cellular Biochemistry, Supplement 14C, UCLA Symposium on Molecular & Cellular Biology, 3 February - 11 March 1990, abstract CK302, G. Corona et al.: "Properties of anti-peptide antibodies raised against the synthetic peptide 20-36 of nerve growth factor", page 53, see the abstract *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1050757A1 (fr) * 1999-05-03 2000-11-08 Evotec BioSystems AG Méthodes de diagnostic ou de traitement de maladies neuropsychiatriques basées sur des taux accrus du NGF (Nerve Growth Factor) dans la fluide cérébrospinale
WO2000067033A1 (fr) * 1999-05-03 2000-11-09 Evotec Biosystems Ag Procedes permettant de diagnostiquer ou traiter la maladie d'alzheimer
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding

Also Published As

Publication number Publication date
CN1058846A (zh) 1992-02-19
EP0533779A1 (fr) 1993-03-31
IT1243281B (it) 1994-05-26
IT9041626A0 (it) 1990-06-12
AU7969091A (en) 1992-01-07
IL98466A0 (en) 1992-07-15
IT9041626A1 (it) 1991-12-12

Similar Documents

Publication Publication Date Title
US5702905A (en) Monoclonal antibody to human ventricular myosin light chains
US5792606A (en) Nucleic acid hybridization based assay for determining a substance of interest
WO1996010076A1 (fr) Anticorps monoclonal contre la troponine i cardiaque humaine
US5534431A (en) Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
Witkowski et al. Enzyme-linked immunosorbent assay for an octapeptide based on a genetically engineered fusion protein
US20040248216A1 (en) Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US7094551B2 (en) Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
EP0221282B1 (fr) Essai sandwich récepteur-anticorps
WO1991019982A1 (fr) Procede de determination de polypeptides et de proteines dans les solutions et les fluides biologiques
JP3370697B2 (ja) 診断試験系における一定の融合パートナーおよび可変抗原部分から成る組換え融合タンパク質での画定されたコーティング
US5437981A (en) Method for the immunological determination of ligands
WO2003074549A2 (fr) Test d'anticorps anti-ingap
EP0106615A2 (fr) Essai de la partie libre de substances dans des liquides biologiques
KR940008091B1 (ko) 리간드의 면역학적 검출방법
JP7066142B2 (ja) 試料に含まれるペリオスチン測定の感度の改善方法
AU2007244153B2 (en) Prostasin partial peptide and anti-prostasin antibody
JP2878317B2 (ja) ラミニン測定試薬
HUT61620A (en) Method for quantitative detecting biological active form of human neuro-growth factor /ngf/
JPH07117534B2 (ja) ヒトプロテインｓに対するモノクローナル抗体を用いた免疫学的測定試薬及びキット
JPH0968527A (ja) モノクローナル抗体、これを産生する融合細胞、並びに、これを利用した蛋白質リン酸化酵素活性の免疫学的測定方法及び測定キット
JP2000069963A (ja) アポリポプロテインｅ４特異モノクローナル抗体
JPH0712811A (ja) ビタミンｂ１２を決定するためのイムノアッセイ、ならびにそのための試薬およびキット
JPH11236399A (ja) モノクローナル抗体
JP2000266750A (ja) ミッドカインの免疫学的測定方法
JPH055737A (ja) 新規な酵素標識モノクローナル抗体、それを用いたメタンフエタミン測定用キツトおよび測定法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA HU JP KR NO PL US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991911244

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991911244

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991911244

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA